{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:57:13Z","timestamp":1788487033498,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese International Medical Exchange Foundation","award":["Z-2021-46-2101"],"award-info":[{"award-number":["Z-2021-46-2101"]}]},{"name":"Chinese International Medical Exchange Foundation","award":["Z-2021-46-2101-2023"],"award-info":[{"award-number":["Z-2021-46-2101-2023"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Cryptococcal meningitis is caused by\n                      <jats:italic toggle=\"yes\">Cryptococcus neoformans<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Cryptococcus gattii<\/jats:italic>\n                      , predominantly affects immunocompromised host. Resistance to amphotericin B poses therapeutic challenges, especially in immunocompetent individuals, where evidence is scarce.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      This study reports a case of an old immunocompetent male diagnosed with amphotericin B-resistant\n                      <jats:italic toggle=\"yes\">C neoformans<\/jats:italic>\n                      meningitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Amphotericin B-resistant\n                      <jats:italic toggle=\"yes\">C neoformans<\/jats:italic>\n                      meningitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>\n                      Treatment failure occurred with both induction regimens (amphotericin B deoxycholate\/fluconazole for 14 days followed by fluconazole\/flucytosine for 29 days), then used salvage therapy combining amphotericin B colloidal dispersion (ABCD) in this amphotericin B-resistant\n                      <jats:italic toggle=\"yes\">C neoformans<\/jats:italic>\n                      meningitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>\n                      Successful salvage therapy with ABCD\/flucytosine was achieved in a case of amphotericin B-resistant\n                      <jats:italic toggle=\"yes\">C neoformans<\/jats:italic>\n                      meningitis. However, the patient ultimately succumbed to multidrug-resistant\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      meningitis secondary to prolonged dexamethasone use for ABCD infusion reaction prophylaxis, which induced significant immunosuppression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      ABCD is a feasible alternative treatment for amphotericin B-resistant\n                      <jats:italic toggle=\"yes\">C neoformans<\/jats:italic>\n                      meningitis. During prolonged ABCD therapy, pharmacists must implement pharmaceutical care to ensure medication safety and mitigate adverse effects, thereby preventing treatment discontinuation or treatment failure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043862","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:01:07Z","timestamp":1756494067000},"page":"e43862","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The treatment of amphotericin B-resistant C neoformans meningitis: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"given":"Liang","family":"Long","sequence":"first","affiliation":[{"name":"Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzi","family":"Yan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Xiao","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","first-page":"1911","article-title":"Epidemiological current situation and research progress on the drug resistance mechanisms of Cryptococcus neoformans infection in newborns.","volume":"41","author":"Zhu","year":"2022","journal-title":"Mycosystema"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"e23213","DOI":"10.1097\/MD.0000000000023213","article-title":"Cryptococcosis caused by Cryptococcus gattii: 2 case reports and literature review.","volume":"99","author":"Xue","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R3-20260406","first-page":"1093","article-title":"Consensus among Chinese experts on the diagnosis of cryptococcal meningitis associated with non-human immunodeficiency virus.","volume":"56","year":"2023","journal-title":"Chin J Neurol"},{"key":"R4-20260406","first-page":"108","article-title":"Clinical progress in the treatment of cryptococcal meningitis with amphotericin B.","volume":"32","author":"Li","year":"2019","journal-title":"Clin Misdiagnosis Misther"},{"key":"R5-20260406","first-page":"763","article-title":"Research progress on drug resistance mechanisms and antimicrobial agents of cryptococcus.","volume":"36","author":"Luo","year":"2020","journal-title":"Chin J Zoonoses"},{"key":"R6-20260406","first-page":"518","article-title":"Fungal species distribution and drug resistance monitoring of clinical isolates in Sichuan Province in 2021.","volume":"44","author":"Xian","year":"2023","journal-title":"Int J Laboratory Med"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/apc.2006.20.227","article-title":"Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS.","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"R8-20260406","first-page":"e11101","article-title":"Effective voriconazole in an immunocompetent patient with amphotericin B resistant systemic cryptococcal granulomatosis.","volume":"12","author":"Serraj sr","year":"2020","journal-title":"Cureus"},{"key":"R9-20260406","first-page":"269","article-title":"Clinical characteristics and drug susceptibility analysis of Cryptococcus neoformans infections in a Chongqing hospital: a 5-year retrospective study.","volume":"17","author":"Zhang","year":"2022","journal-title":"Chin J Mycol"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/mmy\/myw101","article-title":"Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole.","volume":"55","author":"Kano","year":"2017","journal-title":"Med Mycol"},{"key":"R11-20260406","first-page":"20","article-title":"Study on the antifungal effect of amphotericin B combined with fluconazole at different time points.","volume":"29","author":"Zhu","year":"2021","journal-title":"J Dental Prevent Treat"},{"key":"R12-20260406","first-page":"312","article-title":"A study on the drug concentration and the relevance between concentration and effectiveness of liposomal amphotericin B in the treatment of cryptococcal meningitis.","volume":"22","author":"Yang","year":"2022","journal-title":"J Tropical Med"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities.","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"R15-20260406","first-page":"443","article-title":"Safety and efficacy of amphotericin B cholesterol sulfate complex for salvage therapy of invasive fungal diseases.","volume":"23","author":"Cao","year":"2023","journal-title":"Chin J Infect Chemother"},{"key":"R16-20260406","first-page":"303","article-title":"Guidelines for the use of amphotericin B cholesterol sulfate complex for injection.","volume":"35","author":"Zhao","year":"2022","journal-title":"J Clin Hematol"},{"key":"R17-20260406","first-page":"7","article-title":"Pharmaceutical properties and clinical applications of different formulations of amphotericin B.","volume":"20","author":"Kong","year":"2022","journal-title":"Clin Medic J"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2016 update by the Infectious Diseases Society of America (IDSA).","volume":"62","author":"Perfect","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R19-20260406","first-page":"230","article-title":"Multidisciplinary expert consensus on the clinical rational application of different formulations of amphotericin B (2024 edition).","volume":"63","year":"2024","journal-title":"Zhonghua Nei Ke Za Zhi"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:00:36Z","timestamp":1775455236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":19,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043862","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}